This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Mylinax, Movectro (EU), oral cladribine
Description: Oral cladribine is a purine nucleoside analogue that interferes with the behavior and the proliferation of certain white blood cells, particularly lymphocytes, which are involved in the pathological process of multiple sclerosis. In dividing cells, purine analogs act to inhibit ribonucleotide reductase which results in the inhibition of DNA synthesis while in resting cells, they cause DNA strand breaks which results in cell death (apoptosis).
Deal Structure: Serono S.A. and IVAX Corporation signed a worldwide agreement in October 2002 to develop and commercialize IVAX's cladribine. Under terms of the agreement, IVAX will receive a series of undisclosed milestone payments and will also receive royalties on sales of the product, once marketed.
In January 2007, the acquisition of Serono S.A. (now Merck Serono S.A.) by Merck KGaA and the integration of the business with the former Merck KGaA Ethicals Division was completed. Merck Serono is now the division of Merck KGaA which specializes in prescription pharmaceuticals. Its North American business operates in the United States and Canada under EMD Serono.
Partners: Teva Pharmaceutical Industries Ltd.
Cladribine Tablets News
Additional information available to subscribers only: